Inactive Instrument

All News DiNonA Inc.

Equities

A086080

KR7086080009

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

An unknown buyer agreed to acquire approximately 16.5% stake in DiNonA Inc. from Kumho HT, Inc for KRW 19.9 billion.	03/21/03	CI
Kumho HT, Inc. completed the acquisition of remaining 81% stake in DiNonA Inc..	27/21/27	CI
Samsung Biologics Inks Development Partnership with Dinona for Potential COVID-19 Treatment	20/20/20	CI
DiNonA Inc. completed the acquisition of 9.25% stake in Hwail Pharmaceutical Co.,Ltd. from Park, Pil Joon.	30/20/30	CI
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 20.02 billion in funding from DiNonA Inc.	29/20/29	CI
DiNonA Inc. agree to acquire 9.25% stake in Hwail Pharmaceutical Co.,Ltd. from Park, Pil Joon for KRW 30.8 billion	17/20/17	CI
Kumho HT, Inc. agreed to acquire remaining 81% stake in DiNonA Inc. for approximately KRW 170 billion.	27/20/27	CI
DiNonA Inc. announced that it has received KRW 19.999996625 billion in funding	31/20/31	CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 20.02 billion in funding from DiNonA Inc.	30/20/30	CI
DiNonA Inc. announced that it expects to receive KRW 39.999995596 billion in funding from Korea Fixed-Income Investment Advisory, Midasdong-a Investment Co.,Ltd., S-MAC CO., Ltd., Kumho HT, Inc.	08/20/08	CI
DiNonA Inc. announced that it expects to receive KRW 19.999996625 billion in funding	01/20/01	CI
Lumimicro Co., Ltd cancelled the acquisition of DiNonA Inc..	18/19/18	CI
Lumimicro Co., Ltd agreed to acquire DiNonA Inc. for approximately KRW 130 billion.	27/19/27	CI
DiNonA Inc. has withdrawn its IPO.	12/18/12	CI
DiNonA Inc. announced that it has received KRW 18 billion in funding from S-MAC CO., Ltd.	28/18/28	CI
DiNonA Inc. announced that it expects to receive KRW 18 billion in funding from S-MAC CO., Ltd.	27/18/27	CI
DiNonA Inc. has filed an IPO.	30/15/30	CI
3SBio Inc. Signs Exclusive Patent License Agreement with DiNonA Inc. for Leukotuximab	08/14/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer